

# Chronic Myelogenous Leukemia Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

**Stage:**  New diagnosis or  Relapse

**Line of Treatment:**  First Line  Second Line  Third Line  Third Line +

**ECOG Performance Status:**  0  1  2  3  4

**Biomarkers:**

CML Phase:  Chronic Phase  Accelerated Phase  Lymphoid Blast Phase  Myeloid Blast Phase  Not Reported

Imatinib resistant or intolerant:  Yes  No

Philadelphia chromosome:  Positive  Negative

T315I:  Positive  Negative

Mutation:  V299L  T315I

---

## First Line Therapy

Dasatinib\* (Sprycel)

Imatinib (Gleevec)

---

## Second Line Therapy | Following treatment failure, suboptimal response ‡, or intolerance to First Line Therapy

Bosutinib (Bosulif)

Dasatinib (Sprycel)

Nilotinib\*\* (Tasigna) **For patients with V299L mutation**

Ponatinib† (Iclusig) **For patients with T315I mutation**

\*For patients who are intermediate or high-risk Sokal or Hasford Score:

Sokal: Intermediate Risk=0.8-1.2; High Risk>1.2

Hasford: Intermediate Risk=781-1480; High Risk>1480

\*\*For patients with V299L mutation

† For patients with T315I mutation

‡ Defined as lack of complete hematologic response or BCR-ABL1 transcripts>10% (IS) or lack of partial cytogenetic response on bone marrow cytogenetics.

